Some studies have reported that high expression of METTL3 is significantly associated with the clinicopathological characteristics and poor survival in STAD patients and that knocking out METTL3 can inhibit cell proliferation, migration, and invasion. Here, METTL3 is linked to gastric adenocarcinoma.